abstract |
Novel nucleoside analogs, such as 3-(beta-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-2-fluoropyridine, 3-(beta-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-pyridin-2-one, 3-(beta-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, 3-(alpha-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-2-fluoropyridine, 5-(beta-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-2-bromopyridine, 5-(alpha-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-2-bromopyridine, 5-(beta-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-pyridin-2-one, 5-(alpha-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-pyridin-2-one, 5-(beta-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-2-aminopyridine, 5-(beta-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-pyridin-2-(4-nitrophenylethyl)-one, and 5-(alpha-<SMALLCAPS>D</SMALLCAPS>-Ribofuranosyl)-2-aminopyridine; process for their synthesis and incorporation into polynucleotides. |